Skip to content

The effect of intelligent exercise rehabilitation on knee osteoarthritis: a randomised controlled clinical trial

The effect of intelligent exercise rehabilitation on knee osteoarthritis: a randomised controlled clinical trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500101644
Enrollment
Unknown
Registered
2025-04-28
Start date
2025-05-02
Completion date
Unknown
Last updated
2025-05-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Knee osteoarthritis

Interventions

The control group:the control group received the same exercise training with traditional video guidance.
The experimental group:The experimental group received exercise training based on AI motion feedback with the support of the app,

Sponsors

Zhujiang Hospital, Southern Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
38 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) According to the American College of Rheumatology (ACR) clinical classification criteria of knee osteoarthritis. (2) Aged 38-75 years; (3) Knee osteoarthritis confirmed by imaging, Kellgren-Lawrence grade I-III; (4) According to visual analogue scale (VAS) score >= 3; (5) Able to listen, speak, read and understand Chinese, able to use mobile devices, able to understand the requirements of the trial, willing to cooperate with the investigators in the trial, and willing to sign informed consent.

Exclusion criteria

Exclusion criteria: 1: Pregnant or nursing women 2: Patients suffering from systemic osteoarthritis, those who have previously undergone surgery on a lower extremity, patients with septic arthritis, and patients with traumatic joint events that are to be treated. 3: The following diagnoses have been made: rheumatoid arthritis, gout, and severe osteoporosis. 4: The existence of chronic pain as a consequence of another pain disorder. 5: The subject has a medical history that includes severe renal, hepatic, cardiac, gastrointestinal and haematological disease. 6: Neurological or psychiatric disorders diagnosed alongside malignancy; 7: The subject has been diagnosed with an atopic or allergic disease. 8: A history of epilepsy or the use of antiepileptic medication is a contraindication. 9: The ingestion of pharmaceuticals that modify the excitability of the cerebral cortex (for instance, sedative-hypnotic drugs or antidepressants) will also be excluded. 10: The patients have used non-steroidal anti-inflammatory drugs in the past 2 weeks 11: The Mini-Mental State Examination (MMSE) scale score is less than 24;

Design outcomes

Primary

MeasureTime frame
Western Ontario and McMaster Universities Osteoarthritis Index(WOMAC);

Secondary

MeasureTime frame
Visual Analogue Scale(VAS);Functional Near-infrared Spectroscopy brain activity;Balance Function;Short Form 12 Health Survey(SF-12);

Countries

China

Contacts

Public ContactTao Fan

Zhujiang Hospital, Southern Medical University

fantaokf@163.com+86 186 8028 8722

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026